Ascendis Pharma A/S (NASDAQ:ASND) Price Target Increased to $289.00 by Analysts at Wells Fargo & Company

Ascendis Pharma A/S (NASDAQ:ASND) had its target price boosted by Wells Fargo & Company from $264.00 to $289.00 in a report published on Tuesday, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

ASND has been the subject of a number of other reports. Jefferies Financial Group upped their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a buy rating in a research report on Tuesday, August 13th. Bank of America upped their price target on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a report on Wednesday, September 4th. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an outperform rating in a research report on Tuesday. TD Cowen decreased their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a buy rating for the company in a research note on Wednesday, September 4th. Finally, Citigroup dropped their price target on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a buy rating on the stock in a research note on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $193.77.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $151.26 on Tuesday. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The firm has a market capitalization of $8.81 billion, a P/E ratio of -15.97 and a beta of 0.63. The business’s 50-day simple moving average is $133.30 and its 200-day simple moving average is $136.64.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Vestal Point Capital LP acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at approximately $78,719,000. GSA Capital Partners LLP bought a new position in shares of Ascendis Pharma A/S in the 1st quarter worth about $992,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Ascendis Pharma A/S during the fourth quarter worth about $5,779,000. Finally, Perceptive Advisors LLC bought a new position in Ascendis Pharma A/S in the fourth quarter worth about $16,648,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.